Linked Data API

Show Search Form

Search Results

759737
star this property registered interest false more like this
star this property date less than 2017-09-12more like thismore than 2017-09-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medicines and Healthcare products Regulatory Agency: Finance more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what the budget was of the Medicines and Healthcare Products Regulatory Agency in each of the last 10 years for which figures are available. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 10224 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-09-18more like thismore than 2017-09-18
star this property answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) for each of the last 10 years is shown in the following table. The majority of the Agency’s funding is from fees.</p><table><tbody><tr><td><p> </p></td><td><p>2016/7</p></td><td><p>2015/16</p></td><td><p>2014/15</p></td><td><p>2013/14</p></td><td><p>2012/13</p></td><td><p>2011/12</p></td><td><p>2010/11</p></td><td><p>2009/10</p></td><td><p>2008/09</p></td><td><p>2007/08</p></td></tr><tr><td><p>Page number[1]</p></td><td><p>88</p></td><td><p>81</p></td><td><p>86</p></td><td><p>80</p></td><td><p>56</p></td><td><p>42</p></td><td><p>44</p></td><td><p>51</p></td><td><p>52</p></td><td><p>35</p></td></tr><tr><td><p> </p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td><td><p>£’000</p></td></tr><tr><td><p>Total Trading Income</p></td><td><p>157,293</p></td><td><p>152,963</p></td><td><p>152,767</p></td><td><p>141,813</p></td><td><p>108,815</p></td><td><p>117,247</p></td><td><p>121,387</p></td><td><p>112,690</p></td><td><p>112,812</p></td><td><p>93,463</p></td></tr></tbody></table><p> </p><p>Information about the Agency’s funding is published in the Annual Report and Accounts.</p><p>The MHRA’s Annual Report and Accounts for each year is published on the Gov.UK website at:</p><p><a href="https://www.gov.uk/government/publications?keywords=&amp;publication_filter_option=corporate-reports&amp;topics%5B%5D=all&amp;departments%5B%5D=medicines-and-healthcare-products-regulatory-agency&amp;official_document_status=all&amp;world_locations%5B%5D=all&amp;from_date=&amp;to_date" target="_blank">https://www.gov.uk/government/publications?keywords=&amp;publication_filter_option=corporate-reports&amp;topics%5B%5D=all&amp;departments%5B%5D=medicines-and-healthcare-products-regulatory-agency&amp;official_document_status=all&amp;world_locations%5B%5D=all&amp;from_date=&amp;to_date</a></p><p>[1] Page number in the Annual Report and Accounts of the MHRA for each of the years since 2007/08</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property question first answered
less than 2017-09-18T14:27:57.05Zmore like thismore than 2017-09-18T14:27:57.05Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
759738
star this property registered interest false more like this
star this property date less than 2017-09-12more like thismore than 2017-09-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medicines and Healthcare products Regulatory Agency more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many products were seized by the Medicines and Healthcare Products Regulatory Agency in each of the last 10 years for which figures are available. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 10225 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-09-18more like thismore than 2017-09-18
star this property answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the United Kingdom Regulatory Agency with responsibility for the regulation of medicinal products (for human use) and medical devices and also acts as the law enforcement authority with statutory powers including rights of entry, inspection and seizure of products.</p><p> </p><p>Medicinal products are not ordinary consumer goods and, consequently, there is strict legislative control on their sale, supply, manufacture and distribution. Medicines that do not comply with regulatory requirements pose potential health risks and once identified, either in the UK or at the UK border, are liable to detention and seizure.</p><p> </p><p>The tables below set out the number of units / doses seized yearly.</p><p>Seizures by MHRA on operational activities.</p><table><tbody><tr><td><p>OPS seizures</p></td><td><p>Units/doses</p></td></tr><tr><td><p>2009-10</p></td><td><p>244,627</p></td></tr><tr><td><p>2010-11</p></td><td><p>528,769</p></td></tr><tr><td><p>2011-12</p></td><td><p>1,383,495</p></td></tr><tr><td><p>2012-13</p></td><td><p>512,633</p></td></tr><tr><td><p>2013-14</p></td><td><p>266,545</p></td></tr><tr><td><p>2014-15</p></td><td><p>1,079,570</p></td></tr><tr><td><p>2015-16</p></td><td><p>244,627</p></td></tr><tr><td><p>2016-17</p></td><td><p>2,721,673</p></td></tr><tr><td><p>2017- date</p></td><td><p>285,649 *</p></td></tr><tr><td><p> </p></td><td><p>7,267,588</p></td></tr></tbody></table><p /><p>Note: *this figure is year to date</p><p> </p><p>Seizures made on Operation Pangea</p><p> </p><p>Operation Pangea is a global initiative targeting illegal online sales of medical products.</p><p> </p><table><tbody><tr><td><p>Pangea Seizures from Operation Pangea</p></td><td><p>Units/doses</p></td></tr><tr><td><p>2007</p></td><td><p>100,000</p></td></tr><tr><td><p>2008</p></td><td><p>200,000</p></td></tr><tr><td><p>2009</p></td><td><p>334,000</p></td></tr><tr><td><p>2010</p></td><td><p>296,711</p></td></tr><tr><td><p>2011</p></td><td><p>94,806</p></td></tr><tr><td><p>2012</p></td><td><p>2,100,000</p></td></tr><tr><td><p>2013</p></td><td><p>3,700,000</p></td></tr><tr><td><p>2014</p></td><td><p>3,600,000</p></td></tr><tr><td><p>2015</p></td><td><p>6,200,000</p></td></tr><tr><td><p>2016</p></td><td><p>4,664,885</p></td></tr><tr><td><p>Seizures made by UK Border Force</p></td></tr><tr><td><p><table><tbody><tr><td><p>Seizures at UK Border</p></td><td><p>Units/doses</p></td></tr><tr><td><p>2013 – September 2017</p></td><td><p>21,641,816</p></td></tr></tbody></table></p></td><td><p> </p></td></tr></tbody></table><p> </p><p> </p><p>To combine, this represents total seizures of 50,199,806 to date.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property question first answered
less than 2017-09-18T14:42:23.477Zmore like thismore than 2017-09-18T14:42:23.477Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
759741
star this property registered interest false more like this
star this property date less than 2017-09-12more like thismore than 2017-09-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading General Practitioners: Migrant Workers more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what his future plans are for the recruitment of GPs from overseas. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 10228 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-09-18more like thismore than 2017-09-18
star this property answer text <p>NHS England aims to recruit at least 2,000 doctors into general practice by 2020/21. This compares to an initial target of 500 doctors over the same period of time.</p><p> </p><p>In order to meet this target, NHS England is expanding its current recruitment programme of doctors from the European Economic Area (EEA) whose general practitioner (GP) training is recognised in the United Kingdom under European law and who already get automatic recognition to join the General Medical Council’s (GMC) GP register.</p><p> </p><p>NHS England is also establishing a Framework Agreement of International Recruitment Providers, to identify potential overseas doctors and support them through the recruitment process, and a GP international recruitment office to run the recruitment operation.</p><p> </p><p>Finally, the Royal College of General Practitioners is working with the GMC to review the curriculum, training and assessment processes for GPs trained outside the EEA, starting with Australia, to identify whether the GP registration process can be streamlined for those doctors whose training is seen as equivalent to the UK GP programme.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property question first answered
less than 2017-09-18T14:44:27.897Zmore like thismore than 2017-09-18T14:44:27.897Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
760897
star this property registered interest false more like this
star this property date less than 2017-09-14more like thismore than 2017-09-14
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Sustainability and Transformation Partnerships more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what the legal status is of an sustainability and transformation partnership board decision. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 105315 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-10more like thismore than 2017-10-10
star this property answer text <p>Sustainability and transformation partnerships (STPs) are not statutory organisations, and do not have legal status or legal duties.</p><p> </p><p>Each STP footprint is convened by a senior leader who has agreed to chair and lead the meetings on behalf of their peers. Each footprint has agreed to its own governance and representation, and all bodies represented on the STP have agreed to abide by its decision making process.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property question first answered
less than 2017-10-10T12:41:53.143Zmore like thismore than 2017-10-10T12:41:53.143Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
767547
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether the six technologies undergoing Commissioning through Evaluation for which a positive commissioning policy is developed will be (a) required to be assessed by the Clinical Priorities Advisory Group for funding and (b) funded through the Innovation and Technology Payment. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 106469 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-17more like thismore than 2017-10-17
star this property answer text <p>NHS England’s Commissioning through Evaluation (CtE) programme provides the opportunity for a limited number of treatments which show promise, but where there is currently insufficient evidence to take a routine commissioning decision, to gain ‘real world’ evidence as part of a formal evaluation programme.</p><p> </p><p>The six procedures undergoing Commissioning through Evaluation are:</p><p> </p><p>- Selective Dorsal Rhizotomy (SDR);</p><p> </p><p>- Selective Internal Radiation Therapy (SIRT);</p><p> </p><p>- Mitraclip™ ;</p><p> </p><p>- Patent Foramen Ovale (PFO) Closure;</p><p> </p><p>- Left Atrial Appendage Occlusion (LAAO); and</p><p> </p><p>- Stereotactic Ablative Body Radiotherapy (SABR).</p><p> </p><p>NHS England has not made an assessment of the cost of continuing to fund the treatments currently in the CtE programme once recruitment has closed as, until the evaluation is complete, the clinical commissioning policy to ‘not routinely commission’ remains in place. However, NHS England recognises the importance of minimising the gap between a CtE scheme closing to new recruits, the updating of its clinical commissioning policy in light of the new evidence and taking final funding decisions.</p><p> </p><p>Similarly, given that treatments that have entered the CTE programme for evaluative purposes are currently covered by a 'not routinely commissioned' clinical policy, no formal assessment has been made of the number of patients who might have accessed this treatment had a 'routinely commissioned’ policy been in place at the point the scheme completed recruitment.</p><p> </p><p>Through the collection and evaluation of data, NHS England is better able to reconsider its clinical commissioning policy for these treatments. Where the evidence generated by the scheme supports a routine commissioning recommendation, final funding decisions are taken in line with NHS England’s published Service Development Policy. This could result in the policy being entered into NHS England’s biannual clinical prioritisation process for funding or, if the relevant criteria are met, being introduced as an ‘in year service development’. Both these routes are supported by advice from NHS England’s Clinical Priorities Advisory Group.</p><p> </p><p>Entry into the CtE programme does not, therefore, signal the start of routine commissioning. Rather, it is a mechanism for generating clinical evidence for innovative new treatments, which are often experimental, that would not normally be selected for National Institute for Health Research funded research.</p><p> </p><p>NHS England supports clinicians who might consider a treatment that is not currently routinely funded by the National Health Service due to insufficient evidence of clinical and / or cost effectiveness and is covered by a time limited CtE scheme. This includes ethics approval where appropriate (for example in the handling of evaluative data), scheme-specific patient information leaflets and formal consenting arrangements so that patients are aware in advance about the questions remaining about the treatment’s effectiveness. Clinicians will be able to guide patients and their families through any available routinely funded NHS treatment options alongside any potentially accessible via the CtE programme.</p><p> </p><p>The timetable for the completion of evaluation reports takes into account the patient follow up period specific to each scheme. For example, the scheme may require data to be submitted at one and two years post treatment to assess whether clinical improvements achieved by a procedure are maintained over a given time period.</p><p> </p><p>The timetable for the six procedures undergoing CtE (which includes issues like access to treatment) are:</p><p> </p><p>- SDR – The National Institute for Health Care and Excellence (NICE) evaluation report expected to be available for publication September 2018;</p><p> </p><p>- SIRT - NICE evaluation report published October 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report;</p><p> </p><p>- Mitraclip™ - NICE evaluation report expected to be available for publication in March 2018;</p><p> </p><p>- PFO Closure - Patient recruitment completed March 2016. NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published;</p><p> </p><p>- LAAO - NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published; and</p><p> </p><p>- SABR – Patient recruitment planned to be completed March 2019. NICE evaluation report expected to be available thereafter.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property grouped question UIN
106470 more like this
106471 more like this
106472 more like this
106473 more like this
106474 more like this
star this property question first answered
less than 2017-10-17T16:36:24.33Zmore like thismore than 2017-10-17T16:36:24.33Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
767548
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether his Department has made funds available to the six procedures undergoing Commissioning through Evaluation to be used when a formal commissioning policy for them is in place. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 106470 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-17more like thismore than 2017-10-17
star this property answer text <p>NHS England’s Commissioning through Evaluation (CtE) programme provides the opportunity for a limited number of treatments which show promise, but where there is currently insufficient evidence to take a routine commissioning decision, to gain ‘real world’ evidence as part of a formal evaluation programme.</p><p> </p><p>The six procedures undergoing Commissioning through Evaluation are:</p><p> </p><p>- Selective Dorsal Rhizotomy (SDR);</p><p> </p><p>- Selective Internal Radiation Therapy (SIRT);</p><p> </p><p>- Mitraclip™ ;</p><p> </p><p>- Patent Foramen Ovale (PFO) Closure;</p><p> </p><p>- Left Atrial Appendage Occlusion (LAAO); and</p><p> </p><p>- Stereotactic Ablative Body Radiotherapy (SABR).</p><p> </p><p>NHS England has not made an assessment of the cost of continuing to fund the treatments currently in the CtE programme once recruitment has closed as, until the evaluation is complete, the clinical commissioning policy to ‘not routinely commission’ remains in place. However, NHS England recognises the importance of minimising the gap between a CtE scheme closing to new recruits, the updating of its clinical commissioning policy in light of the new evidence and taking final funding decisions.</p><p> </p><p>Similarly, given that treatments that have entered the CTE programme for evaluative purposes are currently covered by a 'not routinely commissioned' clinical policy, no formal assessment has been made of the number of patients who might have accessed this treatment had a 'routinely commissioned’ policy been in place at the point the scheme completed recruitment.</p><p> </p><p>Through the collection and evaluation of data, NHS England is better able to reconsider its clinical commissioning policy for these treatments. Where the evidence generated by the scheme supports a routine commissioning recommendation, final funding decisions are taken in line with NHS England’s published Service Development Policy. This could result in the policy being entered into NHS England’s biannual clinical prioritisation process for funding or, if the relevant criteria are met, being introduced as an ‘in year service development’. Both these routes are supported by advice from NHS England’s Clinical Priorities Advisory Group.</p><p> </p><p>Entry into the CtE programme does not, therefore, signal the start of routine commissioning. Rather, it is a mechanism for generating clinical evidence for innovative new treatments, which are often experimental, that would not normally be selected for National Institute for Health Research funded research.</p><p> </p><p>NHS England supports clinicians who might consider a treatment that is not currently routinely funded by the National Health Service due to insufficient evidence of clinical and / or cost effectiveness and is covered by a time limited CtE scheme. This includes ethics approval where appropriate (for example in the handling of evaluative data), scheme-specific patient information leaflets and formal consenting arrangements so that patients are aware in advance about the questions remaining about the treatment’s effectiveness. Clinicians will be able to guide patients and their families through any available routinely funded NHS treatment options alongside any potentially accessible via the CtE programme.</p><p> </p><p>The timetable for the completion of evaluation reports takes into account the patient follow up period specific to each scheme. For example, the scheme may require data to be submitted at one and two years post treatment to assess whether clinical improvements achieved by a procedure are maintained over a given time period.</p><p> </p><p>The timetable for the six procedures undergoing CtE (which includes issues like access to treatment) are:</p><p> </p><p>- SDR – The National Institute for Health Care and Excellence (NICE) evaluation report expected to be available for publication September 2018;</p><p> </p><p>- SIRT - NICE evaluation report published October 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report;</p><p> </p><p>- Mitraclip™ - NICE evaluation report expected to be available for publication in March 2018;</p><p> </p><p>- PFO Closure - Patient recruitment completed March 2016. NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published;</p><p> </p><p>- LAAO - NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published; and</p><p> </p><p>- SABR – Patient recruitment planned to be completed March 2019. NICE evaluation report expected to be available thereafter.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property grouped question UIN
106469 more like this
106471 more like this
106472 more like this
106473 more like this
106474 more like this
star this property question first answered
less than 2017-10-17T16:36:24.393Zmore like thismore than 2017-10-17T16:36:24.393Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
767546
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what assessment his Department has made of the cost of funding the six procedures undergoing Commissioning through Evaluation while they are in the assessment phase. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 106471 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-17more like thismore than 2017-10-17
star this property answer text <p>NHS England’s Commissioning through Evaluation (CtE) programme provides the opportunity for a limited number of treatments which show promise, but where there is currently insufficient evidence to take a routine commissioning decision, to gain ‘real world’ evidence as part of a formal evaluation programme.</p><p> </p><p>The six procedures undergoing Commissioning through Evaluation are:</p><p> </p><p>- Selective Dorsal Rhizotomy (SDR);</p><p> </p><p>- Selective Internal Radiation Therapy (SIRT);</p><p> </p><p>- Mitraclip™ ;</p><p> </p><p>- Patent Foramen Ovale (PFO) Closure;</p><p> </p><p>- Left Atrial Appendage Occlusion (LAAO); and</p><p> </p><p>- Stereotactic Ablative Body Radiotherapy (SABR).</p><p> </p><p>NHS England has not made an assessment of the cost of continuing to fund the treatments currently in the CtE programme once recruitment has closed as, until the evaluation is complete, the clinical commissioning policy to ‘not routinely commission’ remains in place. However, NHS England recognises the importance of minimising the gap between a CtE scheme closing to new recruits, the updating of its clinical commissioning policy in light of the new evidence and taking final funding decisions.</p><p> </p><p>Similarly, given that treatments that have entered the CTE programme for evaluative purposes are currently covered by a 'not routinely commissioned' clinical policy, no formal assessment has been made of the number of patients who might have accessed this treatment had a 'routinely commissioned’ policy been in place at the point the scheme completed recruitment.</p><p> </p><p>Through the collection and evaluation of data, NHS England is better able to reconsider its clinical commissioning policy for these treatments. Where the evidence generated by the scheme supports a routine commissioning recommendation, final funding decisions are taken in line with NHS England’s published Service Development Policy. This could result in the policy being entered into NHS England’s biannual clinical prioritisation process for funding or, if the relevant criteria are met, being introduced as an ‘in year service development’. Both these routes are supported by advice from NHS England’s Clinical Priorities Advisory Group.</p><p> </p><p>Entry into the CtE programme does not, therefore, signal the start of routine commissioning. Rather, it is a mechanism for generating clinical evidence for innovative new treatments, which are often experimental, that would not normally be selected for National Institute for Health Research funded research.</p><p> </p><p>NHS England supports clinicians who might consider a treatment that is not currently routinely funded by the National Health Service due to insufficient evidence of clinical and / or cost effectiveness and is covered by a time limited CtE scheme. This includes ethics approval where appropriate (for example in the handling of evaluative data), scheme-specific patient information leaflets and formal consenting arrangements so that patients are aware in advance about the questions remaining about the treatment’s effectiveness. Clinicians will be able to guide patients and their families through any available routinely funded NHS treatment options alongside any potentially accessible via the CtE programme.</p><p> </p><p>The timetable for the completion of evaluation reports takes into account the patient follow up period specific to each scheme. For example, the scheme may require data to be submitted at one and two years post treatment to assess whether clinical improvements achieved by a procedure are maintained over a given time period.</p><p> </p><p>The timetable for the six procedures undergoing CtE (which includes issues like access to treatment) are:</p><p> </p><p>- SDR – The National Institute for Health Care and Excellence (NICE) evaluation report expected to be available for publication September 2018;</p><p> </p><p>- SIRT - NICE evaluation report published October 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report;</p><p> </p><p>- Mitraclip™ - NICE evaluation report expected to be available for publication in March 2018;</p><p> </p><p>- PFO Closure - Patient recruitment completed March 2016. NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published;</p><p> </p><p>- LAAO - NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published; and</p><p> </p><p>- SABR – Patient recruitment planned to be completed March 2019. NICE evaluation report expected to be available thereafter.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property grouped question UIN
106469 more like this
106470 more like this
106472 more like this
106473 more like this
106474 more like this
star this property question first answered
less than 2017-10-17T16:36:24.267Zmore like thismore than 2017-10-17T16:36:24.267Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
767549
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what advice his Department provides for clinicians who are managing patients who require a technology undergoing the Commissioning through Evaluation programme. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 106472 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-17more like thismore than 2017-10-17
star this property answer text <p>NHS England’s Commissioning through Evaluation (CtE) programme provides the opportunity for a limited number of treatments which show promise, but where there is currently insufficient evidence to take a routine commissioning decision, to gain ‘real world’ evidence as part of a formal evaluation programme.</p><p> </p><p>The six procedures undergoing Commissioning through Evaluation are:</p><p> </p><p>- Selective Dorsal Rhizotomy (SDR);</p><p> </p><p>- Selective Internal Radiation Therapy (SIRT);</p><p> </p><p>- Mitraclip™ ;</p><p> </p><p>- Patent Foramen Ovale (PFO) Closure;</p><p> </p><p>- Left Atrial Appendage Occlusion (LAAO); and</p><p> </p><p>- Stereotactic Ablative Body Radiotherapy (SABR).</p><p> </p><p>NHS England has not made an assessment of the cost of continuing to fund the treatments currently in the CtE programme once recruitment has closed as, until the evaluation is complete, the clinical commissioning policy to ‘not routinely commission’ remains in place. However, NHS England recognises the importance of minimising the gap between a CtE scheme closing to new recruits, the updating of its clinical commissioning policy in light of the new evidence and taking final funding decisions.</p><p> </p><p>Similarly, given that treatments that have entered the CTE programme for evaluative purposes are currently covered by a 'not routinely commissioned' clinical policy, no formal assessment has been made of the number of patients who might have accessed this treatment had a 'routinely commissioned’ policy been in place at the point the scheme completed recruitment.</p><p> </p><p>Through the collection and evaluation of data, NHS England is better able to reconsider its clinical commissioning policy for these treatments. Where the evidence generated by the scheme supports a routine commissioning recommendation, final funding decisions are taken in line with NHS England’s published Service Development Policy. This could result in the policy being entered into NHS England’s biannual clinical prioritisation process for funding or, if the relevant criteria are met, being introduced as an ‘in year service development’. Both these routes are supported by advice from NHS England’s Clinical Priorities Advisory Group.</p><p> </p><p>Entry into the CtE programme does not, therefore, signal the start of routine commissioning. Rather, it is a mechanism for generating clinical evidence for innovative new treatments, which are often experimental, that would not normally be selected for National Institute for Health Research funded research.</p><p> </p><p>NHS England supports clinicians who might consider a treatment that is not currently routinely funded by the National Health Service due to insufficient evidence of clinical and / or cost effectiveness and is covered by a time limited CtE scheme. This includes ethics approval where appropriate (for example in the handling of evaluative data), scheme-specific patient information leaflets and formal consenting arrangements so that patients are aware in advance about the questions remaining about the treatment’s effectiveness. Clinicians will be able to guide patients and their families through any available routinely funded NHS treatment options alongside any potentially accessible via the CtE programme.</p><p> </p><p>The timetable for the completion of evaluation reports takes into account the patient follow up period specific to each scheme. For example, the scheme may require data to be submitted at one and two years post treatment to assess whether clinical improvements achieved by a procedure are maintained over a given time period.</p><p> </p><p>The timetable for the six procedures undergoing CtE (which includes issues like access to treatment) are:</p><p> </p><p>- SDR – The National Institute for Health Care and Excellence (NICE) evaluation report expected to be available for publication September 2018;</p><p> </p><p>- SIRT - NICE evaluation report published October 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report;</p><p> </p><p>- Mitraclip™ - NICE evaluation report expected to be available for publication in March 2018;</p><p> </p><p>- PFO Closure - Patient recruitment completed March 2016. NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published;</p><p> </p><p>- LAAO - NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published; and</p><p> </p><p>- SABR – Patient recruitment planned to be completed March 2019. NICE evaluation report expected to be available thereafter.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property grouped question UIN
106469 more like this
106470 more like this
106471 more like this
106473 more like this
106474 more like this
star this property question first answered
less than 2017-10-17T16:36:24.457Zmore like thismore than 2017-10-17T16:36:24.457Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
767550
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what assessment his Department has made of the number of patients unable to access procedures which are in the assessment phase of the Commissioning through Evaluation programme. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 106473 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-17more like thismore than 2017-10-17
star this property answer text <p>NHS England’s Commissioning through Evaluation (CtE) programme provides the opportunity for a limited number of treatments which show promise, but where there is currently insufficient evidence to take a routine commissioning decision, to gain ‘real world’ evidence as part of a formal evaluation programme.</p><p> </p><p>The six procedures undergoing Commissioning through Evaluation are:</p><p> </p><p>- Selective Dorsal Rhizotomy (SDR);</p><p> </p><p>- Selective Internal Radiation Therapy (SIRT);</p><p> </p><p>- Mitraclip™ ;</p><p> </p><p>- Patent Foramen Ovale (PFO) Closure;</p><p> </p><p>- Left Atrial Appendage Occlusion (LAAO); and</p><p> </p><p>- Stereotactic Ablative Body Radiotherapy (SABR).</p><p> </p><p>NHS England has not made an assessment of the cost of continuing to fund the treatments currently in the CtE programme once recruitment has closed as, until the evaluation is complete, the clinical commissioning policy to ‘not routinely commission’ remains in place. However, NHS England recognises the importance of minimising the gap between a CtE scheme closing to new recruits, the updating of its clinical commissioning policy in light of the new evidence and taking final funding decisions.</p><p> </p><p>Similarly, given that treatments that have entered the CTE programme for evaluative purposes are currently covered by a 'not routinely commissioned' clinical policy, no formal assessment has been made of the number of patients who might have accessed this treatment had a 'routinely commissioned’ policy been in place at the point the scheme completed recruitment.</p><p> </p><p>Through the collection and evaluation of data, NHS England is better able to reconsider its clinical commissioning policy for these treatments. Where the evidence generated by the scheme supports a routine commissioning recommendation, final funding decisions are taken in line with NHS England’s published Service Development Policy. This could result in the policy being entered into NHS England’s biannual clinical prioritisation process for funding or, if the relevant criteria are met, being introduced as an ‘in year service development’. Both these routes are supported by advice from NHS England’s Clinical Priorities Advisory Group.</p><p> </p><p>Entry into the CtE programme does not, therefore, signal the start of routine commissioning. Rather, it is a mechanism for generating clinical evidence for innovative new treatments, which are often experimental, that would not normally be selected for National Institute for Health Research funded research.</p><p> </p><p>NHS England supports clinicians who might consider a treatment that is not currently routinely funded by the National Health Service due to insufficient evidence of clinical and / or cost effectiveness and is covered by a time limited CtE scheme. This includes ethics approval where appropriate (for example in the handling of evaluative data), scheme-specific patient information leaflets and formal consenting arrangements so that patients are aware in advance about the questions remaining about the treatment’s effectiveness. Clinicians will be able to guide patients and their families through any available routinely funded NHS treatment options alongside any potentially accessible via the CtE programme.</p><p> </p><p>The timetable for the completion of evaluation reports takes into account the patient follow up period specific to each scheme. For example, the scheme may require data to be submitted at one and two years post treatment to assess whether clinical improvements achieved by a procedure are maintained over a given time period.</p><p> </p><p>The timetable for the six procedures undergoing CtE (which includes issues like access to treatment) are:</p><p> </p><p>- SDR – The National Institute for Health Care and Excellence (NICE) evaluation report expected to be available for publication September 2018;</p><p> </p><p>- SIRT - NICE evaluation report published October 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report;</p><p> </p><p>- Mitraclip™ - NICE evaluation report expected to be available for publication in March 2018;</p><p> </p><p>- PFO Closure - Patient recruitment completed March 2016. NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published;</p><p> </p><p>- LAAO - NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published; and</p><p> </p><p>- SABR – Patient recruitment planned to be completed March 2019. NICE evaluation report expected to be available thereafter.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property grouped question UIN
106469 more like this
106470 more like this
106471 more like this
106472 more like this
106474 more like this
star this property question first answered
less than 2017-10-17T16:36:24.567Zmore like thismore than 2017-10-17T16:36:24.567Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this
767551
star this property registered interest false more like this
star this property date less than 2017-10-09more like thismore than 2017-10-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what the timetable is for the Commissioning through Evaluation process for (a) Selective Dorsal Rhizotomy, (b) Selective Internal Radiation Therapy, (c) Percutaneuous Mitral Valve Leaflet Repair, (d) Patent Foramen Ovale Closure, (e) Left Atrial Appendage Occlusion and (f) Stereotactic Ablative Radiotherapy. more like this
star this property tabling member constituency Ellesmere Port and Neston more like this
star this property tabling member printed
Justin Madders remove filter
unstar this property uin 106474 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-10-17more like thismore than 2017-10-17
star this property answer text <p>NHS England’s Commissioning through Evaluation (CtE) programme provides the opportunity for a limited number of treatments which show promise, but where there is currently insufficient evidence to take a routine commissioning decision, to gain ‘real world’ evidence as part of a formal evaluation programme.</p><p> </p><p>The six procedures undergoing Commissioning through Evaluation are:</p><p> </p><p>- Selective Dorsal Rhizotomy (SDR);</p><p> </p><p>- Selective Internal Radiation Therapy (SIRT);</p><p> </p><p>- Mitraclip™ ;</p><p> </p><p>- Patent Foramen Ovale (PFO) Closure;</p><p> </p><p>- Left Atrial Appendage Occlusion (LAAO); and</p><p> </p><p>- Stereotactic Ablative Body Radiotherapy (SABR).</p><p> </p><p>NHS England has not made an assessment of the cost of continuing to fund the treatments currently in the CtE programme once recruitment has closed as, until the evaluation is complete, the clinical commissioning policy to ‘not routinely commission’ remains in place. However, NHS England recognises the importance of minimising the gap between a CtE scheme closing to new recruits, the updating of its clinical commissioning policy in light of the new evidence and taking final funding decisions.</p><p> </p><p>Similarly, given that treatments that have entered the CTE programme for evaluative purposes are currently covered by a 'not routinely commissioned' clinical policy, no formal assessment has been made of the number of patients who might have accessed this treatment had a 'routinely commissioned’ policy been in place at the point the scheme completed recruitment.</p><p> </p><p>Through the collection and evaluation of data, NHS England is better able to reconsider its clinical commissioning policy for these treatments. Where the evidence generated by the scheme supports a routine commissioning recommendation, final funding decisions are taken in line with NHS England’s published Service Development Policy. This could result in the policy being entered into NHS England’s biannual clinical prioritisation process for funding or, if the relevant criteria are met, being introduced as an ‘in year service development’. Both these routes are supported by advice from NHS England’s Clinical Priorities Advisory Group.</p><p> </p><p>Entry into the CtE programme does not, therefore, signal the start of routine commissioning. Rather, it is a mechanism for generating clinical evidence for innovative new treatments, which are often experimental, that would not normally be selected for National Institute for Health Research funded research.</p><p> </p><p>NHS England supports clinicians who might consider a treatment that is not currently routinely funded by the National Health Service due to insufficient evidence of clinical and / or cost effectiveness and is covered by a time limited CtE scheme. This includes ethics approval where appropriate (for example in the handling of evaluative data), scheme-specific patient information leaflets and formal consenting arrangements so that patients are aware in advance about the questions remaining about the treatment’s effectiveness. Clinicians will be able to guide patients and their families through any available routinely funded NHS treatment options alongside any potentially accessible via the CtE programme.</p><p> </p><p>The timetable for the completion of evaluation reports takes into account the patient follow up period specific to each scheme. For example, the scheme may require data to be submitted at one and two years post treatment to assess whether clinical improvements achieved by a procedure are maintained over a given time period.</p><p> </p><p>The timetable for the six procedures undergoing CtE (which includes issues like access to treatment) are:</p><p> </p><p>- SDR – The National Institute for Health Care and Excellence (NICE) evaluation report expected to be available for publication September 2018;</p><p> </p><p>- SIRT - NICE evaluation report published October 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report;</p><p> </p><p>- Mitraclip™ - NICE evaluation report expected to be available for publication in March 2018;</p><p> </p><p>- PFO Closure - Patient recruitment completed March 2016. NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published;</p><p> </p><p>- LAAO - NICE evaluation report expected to be available for publication November 2017. A review of the clinical commissioning policy is already underway and will be informed by the NICE evaluation report once published; and</p><p> </p><p>- SABR – Patient recruitment planned to be completed March 2019. NICE evaluation report expected to be available thereafter.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine remove filter
star this property grouped question UIN
106469 more like this
106470 more like this
106471 more like this
106472 more like this
106473 more like this
star this property question first answered
less than 2017-10-17T16:36:24.627Zmore like thismore than 2017-10-17T16:36:24.627Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4418
unstar this property label Biography information for Justin Madders more like this